Stryker Corporation $SYK Shares Sold by Campbell Newman Asset Management Inc.

Key Points

• Campbell Newman Asset Management trimmed its stake in Stryker by 39.8% in Q4, selling 41,820 shares and leaving 63,217 shares valued at about $22.22 million, roughly 1.6% of the fund's portfolio.
• Director Ronda E. Stryker sold 250,000 shares at an average price of $362.92 (≈$90.73 million), cutting her position by 9.23%; corporate insiders now own about 4.6% of the stock.
• Analysts have an average rating of "Moderate Buy" with a mean price target of $421.11, and Stryker recently beat quarterly estimates with EPS of $4.47 (vs. $4.40) and revenue of $7.17 billion, up 11.4% year-over-year.

Campbell Newman Asset Management Inc. trimmed its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 39.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 63,217 shares of the medical technology company's stock after selling 41,820 shares during the quarter. Stryker accounts for about 1.6% of Campbell Newman Asset Management Inc.'s portfolio, making the stock its 25th biggest holding. Campbell Newman Asset Management Inc.'s holdings in Stryker were worth $22,219,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Clayton Financial Group LLC acquired a new stake in Stryker in the 3rd quarter valued at about $26,000. United Financial Planning Group LLC acquired a new stake in Stryker in the 3rd quarter valued at about $27,000. Strive Asset Management LLC acquired a new stake in Stryker in the 3rd quarter valued at about $30,000. ANTIPODES PARTNERS Ltd acquired a new stake in Stryker in the 3rd quarter valued at about $34,000. Finally, Copia Wealth Management lifted its holdings in Stryker by 181.6% in the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock valued at $40,000 after acquiring an additional 69 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. TD Cowen downgraded shares of Stryker from a "buy" rating to a "hold" rating and set a $387.00 price target for the company. in a report on Monday, January 26th. Jefferies Financial Group reissued a "buy" rating and issued a $465.00 price target on shares of Stryker in a report on Wednesday, March 4th. Truist Financial cut their price objective on Stryker from $395.00 to $380.00 and set a "hold" rating on the stock in a report on Wednesday. Evercore set a $390.00 price objective on Stryker in a report on Monday, January 5th. Finally, The Goldman Sachs Group cut their price objective on Stryker from $403.00 to $357.00 and set a "neutral" rating on the stock in a report on Thursday, April 9th. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and an average price target of $421.11.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the company's stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. This represents a 9.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.60% of the stock is owned by corporate insiders.

Stryker Price Performance

NYSE SYK opened at $337.76 on Friday. The stock's 50-day moving average price is $353.28 and its two-hundred day moving average price is $359.79. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The company has a market cap of $129.36 billion, a PE ratio of 40.21, a PEG ratio of 1.99 and a beta of 0.92. Stryker Corporation has a 1 year low of $319.32 and a 1 year high of $404.87.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. The firm had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business's revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.01 EPS. On average, analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker's dividend payout ratio is currently 41.90%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.